# STELLAR-304 (NCT05678673)

> Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05678673
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Exelixis
- Conditions: Non-Clear Cell Renal Cell Carcinoma
- Interventions: XL092; Nivolumab; Sunitinib Malate
- Enrollment: 317
- Primary outcome: Duration of Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), by Blinded Independent Radiology Committee (BIRC)
- Primary outcome: Objective response rate (ORR) as assessed by BIRC per RECIST 1.1

## Commentary we found

- YouTube: 22
- X threads: 21
- Podcasts: 15
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=stellar-304-nct05678673

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05678673", "email": "<work email>"}; the inbox owner confirms by the emailed link.